Nimbus Receives Additional Funding to Further Develop Protein Targets for Drug Development | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nimbus Discovery today announced an extension of its seed round of funding, which will be used to advance drug programs based on its in silco discovery platform.

The funding comes from Bill Gates and Richard Freisner, co-founder of chemical simulation software firm Schrödinger and a professor of chemistry at Columbia University. Atlas Venture, the founding investor in Nimbus, also was a participant.

Nimbus did not disclose the amount of the investment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.